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The expanding and established literature that correlates tumor 
infiltrating lymphocytes (TILs) with outcomes of patients with solid 
tumors has contributed greatly to the appreciation of the interaction 
between the host immune system with neoplastic growth. This 
analysis has been limited to specific tumors, such as melanoma and 
ovarian cancer, and our understanding of TILs in relation to many 
other malignancies has yet to be explored. We review one less well 
studied malignancy, head and neck squamous cell carcinoma 
(HNSCC), and the initial attempts to examine the impact of TILs on 
outcomes of these patients. To provide a context for the discussion of 
TILs and HNSCC, we first review the epidemiology, relevant head 
and neck anatomy, immune responses and discuss the historical data 
regarding the unique immunobiology of these tumors. Finally, with 
this perspective, we describe our current understanding of tumor 
infiltrating lymphocyte data for head and neck cancers.
Keywords: human, head and neck cancer, tumor-infiltrating 
lymphocytes, prognosis, therapy 
Head and neck cancer: A clinical perspective
Pathologically, the vast majority of tumors (95%) that arise in 
the head and neck region are squamous cell carcinomas arising 
from the upper aerodigestive tract epithelium. The progressive 
local growth of head and neck squamous cell carcinomas 
(HNSCCs) impinge on the highly critical functions of speech, 
swallowing and respiration. Current therapies, whether the 
modality is surgery alone or combined with radio- or chemo-
radiotherapy, leave many of these patients with significant 
functional deficits exacting a unique physical, social and 
emotional toll. Although significant advances in the areas of 
reconstructive surgery, minimally invasive surgery, 
chemotherapy and monoclonal antibody therapy have been 
achieved in the last two decades, the overall survival rates for 
patients with these cancers has been minimally affected.
Other tumors of the head and neck region include melanomas 
where the prognostic significance of tumor infiltrating 
lymphocytes (TILs) has been clearly established (1, 2). In 
addition, nasopharyngeal squamous cell carcinomas (NPCs) are 
a group of head and neck tumors that have a biological behavior 
quite distinct from conventional HNSCCs. Therefore, as these 
tumors are strongly associated with Epstein-Barr virus, are 
geographically localized and as a whole are managed differently 
than HNSCCs (3-5), they will not be considered in this review.
Epidemiology
HNSCCs are a significant public health entity in that they 
claim 11,000 lives a year in the United States and represent one 
of the top ten cancers worldwide (6, 7). The overall 5-year 
survival rate for patients with HNSCC is approximately 50%. 
Despite significant advances in the medical and surgical 
treatment of these cancers, this statistic has remained stable for 
decades.
The major independent risk factors for development of these 
tumors are tobacco and alcohol abuse. Many patients have 
simultaneous addictions to both, which synergize to greatly 
increase the risk of tumor development. The habits of betel nut 
and gutkha chewing and reverse smoking, common practices in 
South Asia, are also contributing carcinogenic insults. The 
general decrease in smoking in North America has reduced the 
incidence of these cancers; however, there has been an increased 
incidence of oral tongue, tonsil and base of tongue carcinomas 
in patients under the age of 45, an increase that has been 
attributed to HPV infection in the latter two sites [reviewed in 
(8, 9)].
Immunoediting in head and neck cancer
Human immunosurveillance of HNSCC
Our expanding concepts about TILs and their relation to 
patient prognosis have occurred in the context of a better 
understanding of immunosurveillance. In the last fifteen years, 
this previously abandoned concept has been resurrected by 
analysis of multiple tumor models in mice deficient in a variety 
of immunologically relevant cells and molecules, including T 
and B lymphocytes, IFN-γ, STAT1 and perforin [reviewed in 
(10)]. These data revealed that the immune system does indeed 
protect against the development of primary and chemical 
carcinogen-induced cancers. This result, however, raised the 
question of why organisms with intact immune systems develop 
neoplastic disease. The finding that addressed this issue came 
from analysis of tumors that arose in wild-type hosts compared 
to immunodeficient RAG2-/- lymphocyte deficient hosts. All 
tumor cells (whether wild-type or RAG2-/- derived) formed 
progressively growing sarcomas in RAG2-/- mice. However, 
when assessed for their capacity to form tumors upon 
transplantation into wild-type syngeneic hosts, tumors derived 
from immunocompetent hosts were significantly more 
tumorigenic than those from immunodeficient hosts. Thus, the 
immune system protects against the development of tumors and 
yet drives the generation of tumors that have developed 
mechanisms to evade elimination. These data have been codified 
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as the "Cancer Immunoediting" hypothesis which includes as its 
first phase the older concept of tumor immunosurveillance 
[reviewed in (10)]. One of the key components in these studies 
was the ability to experimentally manipulate mice, which 
allowed the generation of incontrovertible evidence supporting 
the Cancer Immunoediting hypothesis. However, similar 
evidence in human tumors can only be gained indirectly and 
TIL analysis is one of the cornerstones of these studies in 
humans as exemplified by the studies of Galon, Fridman and 
Pagès (11-13).
One clear indication of the contribution of the immune system 
in controlling HNSCC is the relative increase in incidence in the 
context of acquired or iatrogenic immunodeficiency. King et al.
(14) identified premalignant lip leukoplakia in 13% of renal 
transplant patients as compared to 0.6% of control age- and sex-
matched individuals. Of the renal transplant patients with 
leukoplakia, a majority demonstrated dysplastic conversion and 
10% of these patients (i.e. 2/21 patients with leukoplakia) had 
squamous cell carcinoma. Many other reports examining 
databases of transplant recipients have confirmed this increased 
incidence of lip (15, 16) and other cancers (17). In addition, 
analysis of patients who underwent bone marrow 
transplantation for hematologic malignancies also 
demonstrated a 17.4-fold increased risk for oral cancer, which 
was second only to the risk of liver cancer development (18). 
Again, many other studies (which are not mentioned here due to 
space limitations) have confirmed these general findings [for 
example see (19)]. An additional contributing risk factor for 
buccal cancers in patients who have undergone hematopoietic 
stem cell transplantation is chronic graft versus host disease 
(GVHD) that may contribute to local inflammation and tumor 
development (20). Due to the relatively recent appreciation of 
the contribution of HPV to HNSCC, all of these studies lack 
documentation of HPV status in lip and oral tumors in the 
transplant recipients. The increase in infection-related cancers 
in HIV positive and transplant patients has received recent 
attention (21). We discuss this topic in the HPV section below.
Anatomy relevant to HNSCC immunosurveillance
The complex anatomy of the upper aerodigestive tract allows 
for multiple functions including mastication, deglutition, 
phonation and airway maintenance. This portal also serves as 
the entry point to both the gastrointestinal and respiratory 
systems. Thus, cancerous growths in any part of the upper 
aerodigestive tract impinge on multiple overlapping functions. 
The mucosal subsites of the head and neck where tumors 
develop include the nasopharynx, paranasal sinuses, oral cavity, 
oropharynx, larynx and hypopharynx. Patients with tumors that 
develop in the larynx or oral cavity, where subjective symptoms 
manifest earlier, have a clinical behavior quite different than 
patients with tumors in the hypopharynx. Patients present much 
earlier because of symptoms such as hoarseness for laryngeal 
lesions or masses in the oral cavity, whereas lesions in the 
hypopharynx are tolerated much longer and thus these patients 
typically present with advanced disease. This varied clinical 
presentation must also be considered in any TIL analysis of 
tumor samples.
The associated lymphatic drainage of the upper aerodigestive 
tract tumors serves as the first echelon of regional metastatic 
cancer spread. The lymphatic chains within the neck are divided 
into 6 major levels−level I includes the submental and 
submandibular nodes, levels II through IV encompass the 
jugular chain lymph nodes by dividing the nodes into three 
equal segments, level V nodes are in the "posterior triangle" 
which track with the eleventh cranial nerve as it leaves the 
sternocleidomastoid muscle and heads towards the trapezius 
muscle and, finally, level VI nodes are the central compartment 
nodes which surround the trachea near the thyroid gland. More 
recently, tumor involvement in the retropharyngeal lymph 
nodes (which include the node of Rouviere) has garnered 
attention as a site of tumor metastasis that was often missed in 
older surgical approaches (22, 23). A large body of literature 
based on retrospective analysis of primary tumors and their 
associated resected lymph node dissections showed that specific 
lymphatic groups serve as recipients of regional metastases (24-
26). Thus, for example, tumors of the oral cavity (lip and 
anterior floor of the mouth) drain to level I nodes whereas tonsil 
tumors drain to the level II nodes. Lymph node involvement 
with tumor is one of the worst prognostic factors for patients 
with HNSCC (27)−for example, patients with oral tongue cancer 
have close to a 50% decrease in survival if cervical lymph nodes 
are involved with tumor at initial presentation [reviewed in 
(28)]. In addition, patients with extracapsular spread of tumor 
out of the lymph node have been shown to be at high risk for 
recurrent tumor (29-32). The underpinnings of the propensity 
of certain tumors for lymph node involvement remains under 
investigation but likely involves a combination of dependent 
drainage (i.e. certain subsites have easier access to lymphatic 
pathways than other sites) and specific molecular pathways.
The major lymphoid tissues in direct contact with the 
epithelium giving rise to HNSCC are encompassed in the 
Waldeyer's ring, which includes the laterally located palatine 
tonsils, the inferiorly positioned base of the tongue with lingual 
tonsillar tissue, and finally the superiorly based nasopharyngeal 
adenoid pad. How these structures contribute to immune 
responses in the oral cavity is still undefined (see below). 
Importantly, HNSCC originating within these regions 
encompass a significant number of diagnosed cases. Tumors 
arising in the oropharyngeal and nasopharyngeal subsites may 
have a constitutive heavy lymphocyte content complicating 
immunohistochemical analysis of lymphocytes within tumors. 
A second consideration for these subsites is that specific viral 
associations with nasopharyngeal carcinoma (Epstein-Barr 
virus or EBV) and oropharyngeal carcinoma (human papilloma 
virus or HPV) may reflect a viral antigen-specific immune 
response to these tumors rather than to host-derived tumor-
specific antigens (see the separate section on HPV-related 
tumors).
Finally, the specific lymphatic drainage of the subsites is 
variable, thus, early regional lymphatic metastasis from 
supraglottic HNSCC is typical whereas glottic cancers manifest 
a delayed lymphatic involvement. In addition, the supraglottis is 
considered to be a midline structure and thus lymph flow is 
directed to bilateral regional lymphatic structures. It is unclear 
whether this type of increased drainage to regional lymphatics 
by one subsite results in an augmented histologic immune 
response. Clinically, patients with supraglottic tumors do not 
fare as well as similar stage glottic tumors. Thus, a hypothetical 
increase in exposure to the regional lymphatics does not 
translate to better outcomes.
Immunosurveillance of HPV-associated tumors
A significant amount of scientific literature supports an 
oncogenic role for HPV as a causative agent in oropharyngeal 
cancer leading some authors to suggest that we will, or already 
have, reached epidemic proportions (9). As many other excellent 
reviews detail the biology, clinical presentation, behavior and 




treatment of these tumors (9, 33, 34), we limit our discussion to 
the potential immune responses manifest as TILs.
The successful development of an HPV vaccine that targets the 
key oncogenic subtypes 16 and 18 has garnered a significant 
amount of lay press attention, focused the public's awareness on 
cervical cancer etiology and generated a fierce debate about this 
intervention in prepubescent females [for example see (35)]. 
However, the current strategy to vaccinate young girls does not 
take into consideration the vast potential benefit of also 
including young men in this public health campaign. For 
unclear reasons, men disproportionately (at a 2:1 ratio) develop 
HPV-associated oropharyngeal tumors. Although the vaccine is 
not approved for use in males, a benefit in oropharyngeal and 
genital tumors would be gained with immunization. Increased 
public awareness of HPV associations with oropharyngeal 
cancer [for example see (36)] will likely lead to further calls for 
including all youth prior to sexual maturity.
Clearly, in TIL analysis of HNSCC, virus-associated tumors 
must be specifically identified as the infiltrate in these tumors 
may be a reflection of a host T cell response to viral gene 
products. No studies have specifically addressed this issue but 
several investigators have examined the peripheral blood of 
patients with HNSCC for the presence of virus-specific T cells 
using tetramer technology. Both Albers et al. (37) and 
Hoffmann et al. (38) identified a 2-3 fold elevated level of HLA-
A*201 restricted viral E7-specific T cells in the peripheral blood 
of patients with HPV+ HNSCC versus patients with HPV- 
HNSCC or normal controls. Interestingly, Ferris and colleagues 
(37) found that E7-specific cytotoxic T lymphocytes (CTLs) 
expanded from peripheral blood did not directly recognize an 
HLA-A*201 expressing HPV+ tumor cell line. They found a 
significant decrease of antigen processing machinery 
components in this cell line and in primary HPV+ tumors and 
determined that interferon-gamma (IFN-γ) pre-treatment of the 
cell line greatly enhanced CTL recognition. Thus, these 
investigators postulated that although virus-specific CTLs exist 
in HPV+ HNSCC patients, immune escape occurred due to the 
inability of these CTLs to recognize the tumor. As we gain a 
better understanding of HPV antigens and HNSCC immune 
evasion mechanisms, these viral antigens may emerge as a 
means to target this subset of tumors.
Tumor antigens and recognition of HNSCC
Some of the most significant data supporting immune 
recognition of tumors derives from the identification of specific 
tumor antigens. The HPV-derived antigens described above 
obviously develop in the context of host recognition of viral 
machinery. However, similar to other tumors, efforts to identify 
novel tumor-derived products using serological identification or 
tumor-specific cytotoxic T lymphocytes (CTLs) have resulted in 
the discovery of both novel HNSCC-specific and common 
cancer/testis (CT) antigens (39-47). These studies are 
summarized in Table 1. Immunotherapy using these antigens 
for vaccination is at an early stage in HNSCC (48).
Development of oral tolerance in anti-HNSCC immune responses
Just as a grasp of the gross anatomy of the head and neck is a 
prerequisite for understanding the biology of HNSCC, 
understanding the local immunologic "anatomy" and immune 
response is important in the context of examining TIL 
responses. Similar to the gastrointestinal tract and brain, there 
are important differences in the local response that are a 
consideration in how an individual develops a reaction to a 
growing tumor, and this may play a role in the development of 
any immunotherapeutic strategy. However, as opposed to the 
gastrointestinal tract, fewer studies are available, and the vast 
majority is derived from the dental literature which is focused 
on chronic adult periodontitis in the oral cavity, or studies where 
application of allergens to the nasal mucosa is used to examine 
immune responses. We review some of these studies due to their 
relevance in host responses to cancer development, especially in 
the context of tolerogenic mechanisms driven by oral antigen 
exposure.
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The upper aerodigestive tract environment is bathed in 
approximately 1 liter of saliva per day which helps in digestion, 
via the α-amylase and lingual lipase enzymes, and in deglutition 
(49). Saliva also serves an immunologic function in that it is rich 
in anti-microbial peptides and IgA. The mucosa of the oral 
cavity and oropharynx also acts as a barrier where one finds 
keratinization over areas that encounter shear forces (such as the 
tongue and hard palate) with the remainder having a 
nonkeratinized epithelium [reviewed in (50)]. This barrier 
function is distinct from skin in that there is significant 
permeability and vascularization, which presumably allows 
sampling of antigens in the oral cavity. Similar to the bacterial 
load within the gastrointestinal (GI) tract, the oral cavity has 
over 500 distinct bacterial species that exist in a commensal 
relationship (51). The development of tolerance to these bacteria 
and the lack of inflammatory reactions in the oral cavity clearly 
suggests that a mechanism to induce tolerance exists that likely 
parallels that seen in the GI tract.
Here a distinction must be drawn between oral tolerance 
driven by gut exposure to antigens and oral mucosal tolerance 
where the structures in the oral cavity drive 
immunosuppression. The former, which has been extensively 
reviewed, is a well-studied mechanism whereby GI tract 
antigens are sampled by specific cells [including CX3CR1+ 
dendritic cells (52)], transported to mucosa-associated 
lymphoid tissues (MALT - including Peyer's patches and 
mesenteric lymph nodes) and subsequently induce tolerogenic 
responses via specific cell populations (i.e. IL-10 producing 
regulatory T cells) and cytokines such as TGF-β. These 
mediators in turn suppress inflammatory responses driven by 
Th1 and Th17 cells, which allows tolerance to commensal 
organisms and food/environmental antigens. In contrast, oral 
mucosal tolerance is a less well-defined mechanism where 
similar sampling and transport to undefined inductive sites also 
induces a tolerogenic state. This is well illustrated in the example 
of adolescents who have nickel containing dental appliances 
who then demonstrate reduced T cell mediated responses (53). 
More recently, sublingual immunotherapy (SLIT) has been 
gaining popularity as a means to induce tolerance to 
environmental allergens [reviewed in (54, 55)].
Dendritic cells (DCs) are at the front line of the immunologic 
infrastructure and have initial contact with antigen. Studies in 
the sublingual region of BALB/c mice identified a rich network 
of CD11b+ CD11c+ cells that were also MHC class II+, 
expressed the CD40, CD80 and CD86 costimulatory molecules, 
and the CCR6 chemokine receptor (56)−cellular features which 
are similar to Langerhan's cells found in skin. Sublingual 
administration of ovalbumin induced antibody responses, 
specific cytokine expression and T cell proliferation but required 
a cholera toxin adjuvant to achieve significant levels. Studies in 
humans have also identified similar DC populations [reviewed 
in (57)], again suggesting that these cells serve as the sentinels 
for foreign invaders in the oral mucosa.
Once these DCs sample oral antigens, the inductive site(s) 
where the immune response is initiated is most likely in the 
cervical lymph nodes. Inductive sites for tolerance in the gut 
were identified using mice deficient in various components of 
the lymphotoxin family and revealed that mesenteric lymph 
nodes are critical for inducing tolerance (58) whereas the role of 
Peyer's patches was felt to be dispensable. The parallel MALT in 
the head and neck in humans is represented by the lymphoid 
tissue in Waldeyer's ring. Although not providing definitive 
proof (as not all oropharyngeal lymphoid tissue is removed), 
surgical removal of adenoids and tonsils in humans has gone on 
for decades with no evidence of increased infections, 
inflammation or autoimmunity. Clearer evidence has been 
described in mice where tolerance to a nasal challenge with 
ovalbumin was absolutely dependent on the presence of cervical 
lymph nodes (59). Interestingly, transplanting functioning 
peripheral axillary lymph nodes into the cervical region of mice 
that had all neck lymph nodes removed did not allow for 
development of tolerance. However, control cervical lymph 
node transplants into similar mice did show induction of 
tolerance suggesting that regional differences in specific lymph 
node architecture can dictate this immune response. Studies to 
define the inductive sites in mice using the oral cavity as the 
initiating site have not been performed to date. Thus, although 
many of the specifics of oral mucosal tolerance have not been 
defined, significant parallels and differences are emerging with 
respect to the better defined mechanisms in the gut.
With respect to developing cancers in the upper aerodigestive 
tract, how does the propensity of this site for tolerance induction 
to commensal organisms and environmental antigens relate to 
the host response to nascently transformed cells? Although 
speculative, we suggest that this local immune response may 
reduce the host response to developing tumors, which obviously 
would be reflected in any analysis of tumor infiltrating 
lymphocytes. This concept has been proposed for the gut where 
intra-cecal injection of a BALB/c syngeneic colon carcinoma 
showed an increased growth rate compared to the subcutaneous 
flank site (60). These investigators hypothesized that tumor 
exposure through the MALT would result in systemic 
immunosuppressive effects and indeed this was borne out as 
they found an increased concentration of immunosuppressive 
TGF-β in the serum of mice 14 days after subserosal cecal 
implantation of tumor cells relative to the subcutaneous site. 
O'Sullivan and colleagues (61, 62) have proposed the same idea 
in relation to cancers of the foregut.
Escape: How HNSCC evades the immune response
Tumor cells from all sites have evolved multiple pathways for 
both active and passive immune evasion [reviewed in (63)] and 
HNSCC echoes many of these themes [reviewed in (64)]. Many 
early studies examining global immunosuppression induced by 
cancers primarily involved patients with HNSCC (65-69). These 
studies utilized reactivity to 2,4-dinitrochlorobenzene (DNCB) 
as an indicator of cell-mediated immune response, and the 
general sense at that time was that patients with HNSCC were 
more immunocompromised than patients with other cancers 
and that worsening reactivity to DNCB correlated with a poorer 
prognosis for patients (66, 67).
A better understanding of the molecular and cellular basis of 
immune responses and regulation has led to a more detailed 
analysis of the underpinnings of these early studies. Several 
pathways utilized by HNSCC have been delineated to account 
for tumor immune evasion [reviewed in (64)]. Some of these 
mechanisms include immunosuppressive myeloid-derived 
suppressor cells (MDSCs) (64, 70), decreased HLA class I 
expression by tumor cells (71-74), tumor-induced T cell 
apoptosis (75), regulatory CD4+ CD25+ T cells (76, 77), 
galectin-1 expression by tumor cells (78, 79) and tumor-induced 
senescent T cells with suppressor function (80). The 
interrelationships between these putative mechanisms and how 
they may influence TILs has not been explored in detail.
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Studies on TILs in HNSCC.
Current status of TIL analysis in HNSCC
The available studies on TILs in HNSCC are not definitive 
(summarized in Table 2). The major limitation in existing 
reports is the low number of patient samples available for 
analysis and the heterogeneity in tumor stages, which eventually 
impacts the interpretation of histologic data. Given this 
backdrop, specific studies have arrived at conclusions either 
supporting or dismissing the prognostic value of lymphocyte 
infiltration into HNSCC.
As for many other tumor types, initial prognostic studies on 
HNSCC were limited to subjective observation of lymphocyte 
infiltration on H&E (hematoxylin and eosin) stained tumor 
specimens. One detailed study that illustrates this type of 
analysis assessed lymphocyte infiltration into over 200 oral 
squamous cell carcinomas (81). Using multivariate analysis, 
these investigators identified that a weak or limited lymphocyte 
response at the tumor and stromal margin was associated with 
increased locoregional recurrence and decreased overall 
survival. Many other pathologic criteria were also examined but 
the lack of definition of what actually constitutes the 
lymphocytic infiltrate demonstrates the limitation of this 
approach.
The first studies examining specific lymphocytes were 
performed in the 1980s using newly available monoclonal 
antibodies for specific T cells (82). Using a selected cutoff 
number of cells per high power field (HPF), Wolf and colleagues 
identified a survival benefit for patients who had intra-tumoral 
CD4+ T cell, but not CD8+ T cell, infiltration. However, the 
significant limitations in this study included a 9.5 month 
average follow-up (range 2-25 months), limited tumor numbers 
and heterogeneous tumor sites. The largest subset of tumors in 
their 40-patient study was a group of 10 patients with oral cavity 
tumors. In contrast, Guo and colleagues (83) examined 26 
patients, again from diverse subsites, and found a trend towards 
improved survival with increased numbers of all T lymphocyte 
subsets but statistical significance was not achieved. Finally, 
Snyderman et al. (84) performed a fluorescence activated cell 
sorter (FACS) based assay on TIL preparations from 16 patients 
with various stages of HNSCC. These investigators identified a 
better prognosis in patients who had CD4/CD8 ratios less than 1 
and therefore suggested that the lack of CD8 cells in the tumor 
may have led to poorer outcomes. Thus, these early attempts at 
analyzing TILs in HNSCC yielded some provocative but mixed 
results, and ultimately were inconclusive due to the limitations 
described.
Following these initial studies, the attention of immunologists 
studying HNSCC turned away from potential prognostic 
information provided by TILs towards the incapacitating effects 
of the tumor on host immune cells. However, with the renewed 
interest in TIL studies in the current decade, more specific 
evaluation approached the definition of the composition of the 
cellular infiltrate, either directly or indirectly, in the context of 
studies on immunosuppressive molecules. Sewell and colleagues 
(85) generated a tissue microarray containing 48 different 
oropharyngeal squamous cell cancers and analyzed CD3+ T 
cells within these tissue cores (by immunohistochemistry). This 
study concluded that overall tumors that were classified as 
CD3high exhibited decreased rates of metastasis compared to 
those that were CD3low. Interestingly, the largest tumors overall 
(grade T4) had the lowest CD3 levels. However, when the 
tumors were divided between those that were HPV positive and 
those that were HPV negative, this finding only held for the 
virus positive tumors. Notably, 32/48 tumor specimens had 
detectable HPV-16 DNA. Analysis of overall survival in relation 
to CD3 content did not show statistical significance. The 
limitations of this study include the small number of patients 
and the technique for counting the CD3+ cells. The cellular 
infiltrate was graded, not counted, and was limited to the tissue 
core which represented 0.6 mm of the tumor.
Other investigators have examined specific lymphocytic 
infiltration in the context of studies on immunoevasion by 
HNSCC. Le et al. (78) identified the hypoxia inducible 
production of galectin-1 in the supernatants of squamous cell 
carcinoma cell lines. As galectin-1 has been shown to have 
apoptotic effects on T cells, these investigators examined CD3+ 
T cell infiltration in 101 HNSCCs and found that there was a 
significant inverse association between galectin-1 expression 
and CD3+ T cell infiltration. In multivariate analysis, either 
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Figure 1 
Representative histology and IHC for CD3+ T cells in a supraglottic squamous cell carcinoma. (A) H&E stained section showing lymphocytic infiltrate, particularly 
prominent at the periphery of large tumor nests (200x). (B) Low power (200x) view of CD3+ T cell infiltration in peritumoral stroma and into the periphery of large 
tumor nests. (C) High power (400x) view of CD3+ T cell IHC. Abbreviations: P, peritumoral; I, intratumoral.
strong galectin-1 staining or weak CD3+ T cell staining 
predicted for a poor patient outcome.
CD8+ T cell infiltration and patient outcomes were examined 
in two studies which came to opposing conclusions. Ferrone and 
colleagues (73) examined antigen processing machinery (APM) 
deficiencies in HNSCC as a mechanism of immunoevasion and 
also quantified CD8+ T cell infiltration. Using specific 
monoclonal antibodies (mAbs) to various APM components, 
they analyzed 63 tumor specimens from glottic, supraglottic and 
subglottic sites and found LMP2 and HLA class I down 
regulation, in addition to decreased CD8+ T cell infiltration, 
was correlated with poorer patient outcomes. Decreased class I 
molecule expression by tumor cells correlated with decreased 
CD8+ T cell infiltration (P < 0.001). CD8+ T cell infiltration was 
analyzed by dichotomizing patients into those who had more 
than 20 cells/HPF and those that had fewer than 20 cells/HPF 
within the tumor. A significant association for cause specific 
survival (CSS), but not disease free survival (DFS), was 
observed. How CD8+ T cells do not contribute to recurrence but 
do contribute to improved cancer-specific survival is unclear. In 
addition, as opposed to other TIL studies, this study determined 
CD8+ T cell infiltration by counting cells in a 0.25 mm2 area of 
tumor (as opposed to the more typical 10-20 HPFs) and the 
survival curve analysis did not examine CD8+ T cells as a 
continuous variable. Notwithstanding these comments, the 
significant correlation between decreased APM components in 
tumors and decreased CD8+ T cell infiltration does suggest that 
tumor antigens being presented in the context of HLA class I are 
being recognized by specific immune components which impact 
on survival.
In contrast to the study of Ferrone and colleagues (73), 
Badoual et al. (86) reported that CD4+ T cell, but not CD8+ T 
cell, infiltration was significantly correlated with patient 
survival. They examined tissue from 84 patients with HNSCC 
arising from 5 different subsites with the majority of tumors (47/
84; 56%) being stage T3 or T4 and the majority of patients (44/
84; 52%) having regional lymph node metastasis. Surprisingly, 
analysis of intratumoral and stromal regions did not reveal an 
association between CD8+ T cell infiltration and locoregional 
control or overall survival. As expected, better locoregional 
control and overall survival was observed with lower T stage in 
multivariate analysis. Interestingly, better locoregional control 
was observed with increased numbers of CD4+ FoxP3+ 
regulatory T cells, which the authors postulate decrease local 
inflammation thus impeding tumor growth. This finding is in 
contrast to studies in ovarian cancer, where the presence of 
regulatory T cells bode poorly for patients (87). For overall 
survival, only the presence of increased numbers of CD4+ 
CD69+ activated phenotype T cells correlated with improved 
patient outcomes. Thus, this study is the first to correlate CD4+ 
CD69+ T cells in TILs as a positive prognostic factor for overall 
survival.
Finally, our own analysis (JSL and RU, unpublished) of over 35 
supraglottic squamous cell carcinomas did not identify any 
correlation between specific CD3+, CD4+ or CD8+ T cell 
infiltration and survival. We counted 10 HPFs per tumor and 
performed statistical analysis using these counts as a continuous 
variable. A representative section of immunohistochemistry for 
CD3+ T cells infiltrating a supraglottic squamous cell tumor is 
shown in Figure 1.
Additional immune cell subsets within HNSCC
Although the focus on TILs implies antigen-specific 
infiltrating cells, other adaptive and innate hematopoietic cells 
contribute to the HNSCC tumor microenvironment and several 
reports have addressed their possible contribution to tumor 
behavior (64, 76, 88, 89). These other cellular subsets include 
myeloid-derived suppressor cells (MDSCs), FoxP3+ regulatory 
CD4+ T cells, tumor-associated macrophages (TAMs) and 
plasmacytoid dendritic cells (pDCs). MDSCs in mice are a bone 
marrow-derived Gr-1+ CD11b+ immature myeloid population 
that has been shown to inhibit T cell responses by several 
mechanisms, including expressing arginase I which deprives T 
cells of the critical amino acid arginine [reviewed in (63)]. 
HNSCC was one of the first human cancers where similar cells 
were identified as CD34+ progenitor cells that inhibited T cell 
responses (70, 90) and in a small analysis were shown to 
correlate with poor patient outcomes (91). Further, analysis of 
these cells in HNSCC has been limited. A second major 
immunosuppressive subset of cells are regulatory CD4+ T cells 
that express the forkhead/winged-helix transcription factor 
FoxP3 and at least in part mediate their actions via IL-10 and 
TGF-β. Whiteside and colleagues (76) have identified these cells 
in the peripheral blood and TILs of patients with HNSCC. 
Interestingly, these cells persist in the peripheral blood after 
complete tumor eradication in patients with no evidence of 
disease. As detailed above and in contrast to the studies of Curiel 
and colleagues (87), Badoual et al. (86) found that Treg 
infiltration into tumors was correlated with better locoregional 
control.
Macrophage infiltration into tumors including breast, prostate 
and bladder has been shown to correlate with poor patient 
prognosis [reviewed in (92)]. Similarly, Teknos and colleagues 
(89) examined 102 oral cavity HNSCCs and identified that 
TAMs were correlated with an increased propensity for tumors 
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to exhibit regional metastatic capacity and extracapsular 
extension, which are known risk factors for worse patient 
outcomes. Interestingly, this connection also held true for 
smaller grade T1 or T2 tumors where regional metastasis is seen 
less frequently than in advanced tumors. Further mechanistic 
exploration of how macrophages may promote regional 
metastatic activity has not been explored in HNSCC.
Concluding remarks
As we analyzed the literature in preparing this review, it 
became apparent that no definitive studies exist either 
supporting or dismissing the prognostic relevance of TIL 
analysis in HNSCC. As with many studies on human cancer, a 
limited number of samples and diverse stages and subsites 
clouds the interpretation of the available data. In addition, the 
very recent appreciation of HPV-associated HNSCC as a 
relatively distinct clinical entity necessitates a reanalysis of TIL 
studies with viral infection as a dichotomizing variable. The 
significant implications of virus-associated HNSCC and other 
points highlighted in this review indicate arenas for future work 
on the important topic of TILs and HNSCC solid tumor biology.
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